

1 **Title:** Antimalarial Drug Resistance in *Plasmodium falciparum* from Tak Province, Thailand
2 (1998-2001): A TaqMan Array Card Study.

3 **Running Title:** Antimalarial Resistance in Tak, Thailand: 1998-2001 TAC Study

4 Sasikanya Thaloengsook¹, Chaiyaporn Chaisatit¹, Piyaporn Saingam¹, Paphavee Lertsethtakarn¹,
5 Michele Spring¹, Sabaithip, Sriwichai¹, Suporn Pholwat², Jennifer L Guler^{2,3}, Eric Houpt², Brian
6 Vesely¹

7 ¹ Walter Reed Army Institute of Medical Science-Armed Forces Research Institute of Medical
8 Sciences (WRAIR-AFRIMS), Bangkok, Thailand

9 ²Division of Infectious Disease and International Health, Department of Medicine, University of
10 Virginia, Charlottesville, VA, USA

11 ³University of Virginia, Charlottesville, VA, USA

12 **Abstract:**

13 Despite declining malaria cases in Thailand, surveillance in endemic areas is crucial.
14 Retrospectively analyzing samples from Tak province, Thailand, we found prevalent drug-
15 resistant *Plasmodium falciparum*, particularly to mefloquine and sulfadoxine/pyrimethamine.
16 Notably, mutations indicating resistance to artemisinin were detected at low frequencies,
17 suggesting evolving resistance. These findings stress the need for continuous surveillance to
18 guide control strategies and prevent outbreaks, even with decreasing cases, to sustain malaria
19 elimination efforts.

20 **Keywords:** PfKelch13 Mutations, GMS, Plasmodium, TAC

21 Malaria remains a significant public health challenge in the Greater Mekong Subregion (GMS),
22 historically serving as a hotspot for transmission by *Plasmodium falciparum* and *Plasmodium*
23 *vivax*. Despite progress in reducing incidence over the past decade, transmission persists in
24 border areas and remote regions with limited healthcare access (Sudathip et al., 2019).
25 Artemisinin-based combination therapies (ACTs) have been crucial in treatment and control
26 efforts, but artemisinin resistance threatens progress. PfKelch13 mutations are central to this
27 resistance, altering the parasite's response to artemisinin (Ashley et al., 2014). The WHO has
28 identified thirteen validated PfKelch13 markers of resistance (World Health Organization,
29 2022).

30 The earliest documented PfKelch13 mutation linked to resistance dates to 2008, with
31 subsequent high prevalence in *P. falciparum* isolates, especially in border regions and areas
32 with extensive antimalarial drug use (Ménard et al., 2016). Surveillance systems, including the
33 innovative *P. falciparum* TaqMan Array Cards (TACs), play a vital role in monitoring PfKelch13
34 mutations. TACs offer a high-throughput, cost-effective means of detecting genetic markers
35 associated with *P. falciparum*, aiding large-scale surveillance and clinical trials (Pholwat et al.,
36 2017).

37 Our study presents findings from a survey using TaqMan Array Cards (TACs) to assess drug-
38 resistant markers in Mae Sot, Tak, Thailand, from 1998, 1999, and 2001, offering insights into
39 the prevalence and dynamics of artemisinin resistance-conferring PfKelch13 mutations,
40 enhancing understanding of malaria and drug resistance in the GMS (Figure 1). A total of 808
41 archived blood samples were collected during malaria studies evaluating rapid diagnostic tests
42 (RDTs) for *P. falciparum* in Tak Province, Thailand, conducted from 1998 to 2001. These samples
43 were primarily assessed for both mono- and mixed *P. falciparum*/*P. Vivax* infections by smear
44 and were subjected to analysis using TACs. Out of the total samples, 112 were excluded due to
45 the absence of *Plasmodium* spp. or being positive only for *P. vivax*. The remaining 696 samples
46 were confirmed to be positive for *Plasmodium* species, with *P. falciparum* being the most
47 prevalent (Table 1).

48 Using the *Plasmodium* TAC panel, mutations in several key genes associated with drug
49 resistance and malaria biology were analyzed. These genes included PfKelch13, *P. falciparum*
50 CQ-resistant transporter (Pfcr1), Pfdhfr, Pfdhps, cytochrome bc1, and Pfmdr1 *P. falciparum*
51 genes (Table 2). The Pfcr1 mutations at amino acids 72-76 reflect chloroquine resistance,
52 selected for the TAC panel before the discovery of novel mutations' role in piperazine
53 resistance (Muhamad et al., 2013).

54 During the sample collection period, the first-line treatment for uncomplicated *P. falciparum*
55 infection was mefloquine alone or in combination with sulfadoxine/pyrimethamine (S/P), later
56 with artesunate. Mutations conferring mefloquine resistance were observed in Pfmdr1 at
57 positions N86Y, Y184F, and N1042D. Additionally, mutations associated with S/P resistance,
58 particularly in Pfdhfr and Pfdhps, were prevalent. Notably, a double mutation of Pfdhfr at
59 positions 59R and 108N was highly prevalent (>99%), and multiple mutations were observed in
60 Pfdhps, notably 540E and 581G. These mutations were indicative of a strong selection pressure
61 imposed by the widespread use of these antimalarial drugs (Myo Thura Zaw et al., 2020).

62 Analysis of PfKelch13 mutations revealed the presence of mutations at positions P574L, Y493H,
63 and R539T, all confirmed by the WHO to confer resistance to artemisinin (Table 3). These
64 findings suggest the emergence of baseline resistance markers even in the absence of drug
65 pressure, highlighting the adaptive nature of *P. falciparum* to changing drug regimens (Pholwat
66 et al., 2017). Chloroquine ceased being used for *P. falciparum* due to high-level resistance, but
67 it remained first-line for *P. vivax*. While the K to T mutation at position 76 of *pfcr1* is thought to
68 be pivotal in resistance, the 72-76 CVIET combination, indicative of Indonesian lineage, and
69 mutations in 326/356 have been at saturation for at least 15 years, present in 86-98% of
70 samples. No mutations associated with atovaquone resistance were detected.

71 Artemisinin resistance in *P. falciparum* has presented a significant challenge to malaria control
72 efforts in the GMS. Monitoring mutations in the PfKelch13 gene, some strongly associated with
73 artemisinin resistance, has aided national malaria programs in adjusting first-line therapies and
74 increasing control efforts to inhibit transmission (Ménard et al., 2016). With PfKelch13

75 prevalence increasing in East Africa, understanding the emergence and spread of PfKelch13
76 mutations may assist in the prediction and interruption of drug failures there.

77 The study contributes to understanding artemisinin resistance dynamics by detecting the
78 P574L, Y493H, and R539T mutations in samples collected from Tak, Thailand, between 1998
79 and 2001. These mutations were previously reported in Thailand in 2009, highlighting the
80 persistence and spread of resistance alleles over time. The findings underscore the early
81 emergence of resistance in the GMS, consistent with WHO assessments (Ashley et al., 2014).
82 Comparisons with earlier and subsequent studies could provide insights into mutation trends
83 over a decade. The study also ties into related research, emphasizing the importance of
84 ongoing surveillance and intervention efforts to combat anti-malarial resistance. Tools such as
85 TACs offer valuable insights into resistance dynamics, aiding in the development of targeted
86 interventions to address the evolving challenges posed by malaria.

87 The importance of continuous surveillance to monitor resistance profiles and inform malaria
88 control strategies cannot be overstated. Even amid declining malaria case numbers, vigilance is
89 crucial to prevent outbreaks and safeguard elimination efforts. The presence of drug-resistant
90 strains, particularly those resistant to artemisinin, threatens to undermine the progress made in
91 malaria control. The adaptive nature of *P. falciparum*, demonstrated by the observed
92 mutations, highlights the need for adaptable and robust malaria management programs. As
93 resistance markers continue to evolve, the use of advanced molecular techniques, such as TACs,
94 becomes indispensable in providing timely and accurate data to guide public health
95 interventions.

96 This study of archived blood samples from Tak Province, Thailand, using TaqMan Array Cards
97 has provided valuable insights into the prevalence and types of drug-resistant mutations in *P.*
98 *falciparum* and to our knowledge this is the oldest reported PfKelch13 mutations found in the
99 GMS. The identification of key mutations associated with resistance to chloroquine,
100 mefloquine, sulfadoxine/pyrimethamine, and artemisinin underscores the complex and
101 evolving challenge of malaria control. These findings highlight the necessity for ongoing
102 surveillance and adaptive public health strategies to combat the persistent threat of drug-
103 resistant malaria. Advanced molecular tools and comprehensive genetic analysis are crucial in
104 informing and guiding these efforts, ensuring that control measures are both timely and
105 effective. The fight against malaria requires constant vigilance, innovation, and a commitment
106 to understanding the ever-changing landscape of antimalarial resistance.

107

108

109

110


111 Table 1: Distribution of *Plasmodium* spp. infections by TACs

	N=30	N=206	N=460
Year	1998	1999	2001
PF	26	180	378
PF+PV	4	26	76
PF+PM	0	0	4
PF+PV+PM	0	0	1
PF+PV+PO	0	0	1
Negative	5	87	20

112

113

114 Figure 1: A map of the Greater Mekong Subregion (GMS) with the sample site highlighted in
115 Mae Sot District, Tak Province, Thailand.



116

117 Table 2: Summary of TAC results.

Antimalarial drugs and associated genes	Genotype	1998		1999		2001	
		N=30	%	N=206	%	N=460	%
Chloroquine (CQ) and <i>pfcr</i>	72C WT	25	83	203	99	440	96
	73-76 VMNK WT	4	13	3	1	15	3
	73-76 VMNT mutation	4	13	3	1	15	3
	73-76 VIET mutation	26	87	202	98	441	96
	73-76 VIDT mutation	0	0	0	0	0	0
	97H WT	23	77	185	90	434	94
	97Q mutation	0	0	0	0	0	0
	326N WT	0	0	0	0	0	0
	326S mutation	25	83	204	99	442	96
	326D mutation	4	13	2	1	17	4
	356I WT	1	3	7	3	35	8
	356L mutation	4	13	3	1	16	3
	356T mutation	25	83	202	98	415	90
	Atovaquone (ATO) and <i>pfcytB</i>	258I WT	30	100	206	100	460
258M mutation		0	0	0	0	0	0
268Y WT		30	100	205	100	460	100
268S mutation		0	0	0	0	0	0
268C mutation		0	0	0	0	0	0
268N mutation		0	0	0	0	0	0
272K WT		30	100	206	100	459	100
Pyrimethamine (Pyr) and <i>DHFR</i>	272R mutation	0	0	0	0	0	0
	51N WT	8	27	35	17	146	32
	51I mutation	22	73	167	81	332	72
	59C WT	0	0	0	0	0	0
	59R mutation	30	100	203	99	458	100
	108S WT	0	0	0	0	3	1
	108N mutation	30	100	206	100	456	99
Sulfadoxine (Sulf) and <i>DHPS</i>	164I WT	8	27	36	17	102	22
	164L mutation	23	77	170	83	358	78
	436-437SG WT	25	83	168	82	364	79
	436-437AG mutation	7	23	42	20	97	21
	436-437SA mutation	0	0	1	0	16	3
	540K WT	4	13	15	7	64	14
	540E mutation	26	87	183	89	364	79
	581A WT	11	37	55	27	156	34
	581G mutation	19	63	158	77	328	71
Multi-drug resistant (MDR) and <i>pfMDR</i>	613A WT	30	100	205	100	454	99
	613S mutation	0	0	0	0	0	0
	613T mutation	0	0	0	0	1	0
	86N WT	28	93	200	97	388	84
	86Y mutation	2	7	7	3	77	17
	184Y WT	21	70	158	77	343	75
	184F mutation	11	37	54	26	135	29
	1034S WT	30	100	204	99	457	99
	1034C mutation	0	0	0	0	0	0
Artemisinin (Art) and Kelch 13	1042N WT	28	93	196	95	437	95
	1042D mutation	1	3	8	4	18	4
	1246D WT	30	100	204	99	457	99
	1246Y mutation	0	0	0	0	0	0
	446F WT	30	100	205	100	458	100
	446I mutation	0	0	0	0	0	0
	458N WT	30	100	204	99	456	99
	458Y mutation	0	0	0	0	0	0
	493Y WT	30	100	201	98	456	99
	493H mutation	0	0	5	2	0	0
	539R WT	29	97	205	100	455	99
	539T mutation	0	0	0	0	1	0
	543I WT	30	100	203	99	457	99
	543T mutation	0	0	0	0	0	0
	561R WT	28	93	204	99	456	99
	561H mutation	1	3	1	0	1	0
	574P WT	29	97	202	98	457	99
574L mutation	1	3	0	0	0	0	
578A WT	30	100	203	99	457	99	
578S mutation	0	0	0	0	0	0	
580C WT	30	100	205	100	457	99	
580Y mutation	0	0	0	0	0	0	

119 Table 3 PfKelch13 SNPS identified by TAC.

	1998		1999		2001	
	N=30	%	N=206	%	N=460	%
Artemisinin (Art) and Kelch						
WT Kelch 446F	30	100	205	100	458	100
WT Kelch 458N	30	100	204	99	456	99
WT Kelch 493Y	30	100	201	98	456	99
mutation Kelch 493H	0	0	5	3	0	0
WT Kelch539R	29	97	205	100	455	99
mutation Kelch 539T	0	0	0	0	1	0
WT Kelch 543I	30	100	203	99	457	99
WT Kelch 561R	28	93	204	99	456	99
mutation Kelch 561H	1	3	1	0	1	0
WT Kelch 574P	29	97	202	98	457	99
mutation Kelch 574L	1	3	0	0	0	0
WT Kelch578A	30	100	203	99	457	99
WT Kelch 580C	30	100	205	100	457	99
mutation Kelch 580Y	0	0	0	0	0	0

120

121

122 **Acknowledgements:**

123 **Disclaimer:**

124 Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its
125 presentation/publication. The opinions or assertions contained herein are the private views of the
126 author, and are not to be construed as official, or as reflecting true views of the Department of the Army
127 or the Department of Defense. The investigators have adhered to the policies for protection of human
128 subjects as prescribed in AR 70-25.

129 **Ethics:**

130 All participants provided written informed consent and samples were collected under approval the
131 Ethical Review Committee for Research in Human Subjects, Ministry of Public Health (MoPH EC) and
132 Walter Reed Army Institute of Research Institutional Review board under WRAIR #2902

133 **Author's contributions:**

134 **Funding:**

135 This work was supported by the United States Department of Defense Armed Forces Health Surveillance
136 Division-Global Emerging Infectious Disease Surveillance Branch (AFHSD-GEIS): P0005_19_AF. The
137 funding source had no role in the analysis or interpretation of data, preparation of the manuscript or the
138 decision to publish.

139 **References:**

- 140 1. Sudathip P, Kongkasuriyachai D, Stelmach R, Bisanzio D, Sine J, Sawang S, Kitchakarn S, Sintasath
141 D, Reithinger R. The Investment Case for Malaria Elimination in Thailand: A Cost-Benefit
142 Analysis. *Am J Trop Med Hyg.* 2019 Jun;100(6):1445-1453. doi: 10.4269/ajtmh.18-0897. PMID:
143 30994098; PMCID: PMC6553898.
- 144 2. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S,
145 Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroeth S, Pukrittayakamee S, Jittamala P,
146 Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh
147 NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M,
148 Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N,
149 Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA,
150 Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis
151 B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Chalk J, Intharabut B, Silamut K,
152 Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Smithuis F, Hlaing TM, Tun KM, Nwe ML,
153 Barends M, Aung PP, van der Pluijm RW, Dhorda M, Imwong M, Woodrow CJ, Day NP, White NJ,
154 Dondorp AM. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med.*
155 2014 Jul 31;371(5):411-23. doi: 10.1056/NEJMoa1314981. PMID: 25075834; PMCID:
156 PMC4085289.
- 157 3. World Health Organization. Artemisinin resistance and artemisinin-based combination therapy
158 efficacy. World Health Organization. 2022. Available at: <https://www.who.int/news->

159 [room/feature-stories/detail/artemisinin-resistance-and-artemisinin-based-combination-](#)
160 [therapy-efficacy](#)

- 161 4. Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, Rahim-Awab G, Barnadas
162 C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH, Collet L, Cui L, Thakur GD, Dieye A, Djallé D,
163 Dorkenoo MA, Eboumbou-Moukoko CE, Espino FE, Fandeur T, Ferreira-da-Cruz MF, Fola AA,
164 Fuehrer HP, Hassan AM, Herrera M, Hongvanthong B, Houzé S, Ibrahim ML, Jahirul-Karim M,
165 Jiang L, Kano S, Kassa M, Kengne P, Lanza M, Leang R, Leelawong M, Lin K, Mazarati JB, Mayxay
166 M, Menard S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nakazawa S, Namuigi P,
167 Newton PN, Noedl H, Nour BY, Obare P, Ogouyèmi-Hounto A, Omar A, Pillai DR, Rogier C,
168 Rosenthal PJ, Rossan RN, Same-Ekobo A, Sattabongkot J, Shi YP, Sutherland CJ, Swarthout T,
169 Syafruddin D, Tahar R, Tang LH, Touré OA, Tsuyuoka R, Warsame M, Wini L, Zeyrek FY, Zinsou JF,
170 Kwiatkowski D, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O, Wongsrichanalai C,
171 WorldWide Antimalarial Resistance Network Plasmodium falciparum K13 Genotype-Phenotype
172 Study Group. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. *N Engl*
173 *J Med*. 2016 Jun 23;374(25):2453-64. doi: 10.1056/NEJMoa1513137. PMID: 27332904; PMCID:
174 PMC5034794.
- 175 5. Pholwat S, Liu J, Stroup S, Jacob ST, Banura P, Moore CC, Huang F, Laufer MK, Hout E, Guler JL.
176 The Malaria TaqMan Array Card Includes 87 Assays for Plasmodium falciparum Drug Resistance,
177 Identification of Species, and Genotyping in a Single Reaction. *Antimicrob Agents Chemother*.
178 2017 Apr 24;61(5):e00110-17. doi: 10.1128/AAC.00110-17. PMID: 28264857; PMCID:
179 PMC5404514.
- 180 6. Myo Thura Zaw, Tin Aung Hlaing, Aye Mya Thiri Kyaw, Cherry Wah Wah Myint, Jotshna
181 Yonemori, Stuart D. Tyner, Nay Soe Maung, Kan Nagao. 2020. Prevalence of drug-resistant
182 malaria in asymptomatic populations in myanmar: A nationwide study. *The Journal of Infectious*
183 *Diseases*. DOI: 10.1093/infdis/jiz607

184

185